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Introduction
During the last half century, the average life span has increased by 20 years and is expected to increase by another 10 years. Th e global population of age above 65 years will grow from 443 million to 973 million between 2000 and 2030. Th e rapid increase in the elderly population as a result of this prolonged life expectancy has led to increased interest in geriatric medicine.
A progressive decrease in physiological reserves occurs with ageing. When a threshold of decline occurs across multiple organ systems, the syndrome of frailty occurs and as a consequence, frail elderly individuals have a higher susceptibility to stressors and are at high risk for functional defi cits and comorbid disorders, possibly leading to hospitalization and death [1] . Th e phenotype of frailty is referred to as the frailty syndrome and is widely recognized in geriatric medical practice. Although frailty aff ects both musculoskeletal and nonmusculoskeletal systems, sarcopenia (aff ecting the muscular component) remains one of the major components of clinical frailty. Sarcopenia results in a decrease in aerobic capacity of about 10% per decade from the age of 25 to 30 years, because of which, in elderly individuals, activities of daily living will require eff orts that are best of their physical capacity [1, 2] .
Interestingly, despite being a condition resulting in huge fi nancial costs to the individual and state, sarcopenia does not have a broadly accepted clinical defi nition and there is no ICD-9 code for this diagnosis. Similarly, treatment guidelines have not yet been developed. As a result, it is an underdiagnosed and undertreated medical entity. With this review article, an attempt has been made to report on recent advancements in the defi nition and diagnostic criteria for the frailty syndrome and sarcopenia and practical guidelines for the prevention, diagnosis and treatment of both.
Before proceeding any further, it is important to keep in mind that the skeletal muscle has eff ects on a number of vital processes: fi rst, it is responsible for locomotor function, and loss of muscle mass and quality results in weakness and reduced mobility, besides frequent falls and fractures of bones and joint dislocations. Th is is the largest reserve of protein in the body and provides a continuous supply of amino acids to maintain the rate of protein synthesis in other vital tissues during periods of stress, starvation and undernutrition. Skeletal muscle is the primary site of glucose disposal and diminished muscle mass plays a critical role in impaired glucose metabolism in patients with insulin resistance and type 2 diabetes. In addition, skeletal muscle is the major consumer of energy and contributor to the basal metabolic rate in the body and loss of muscle mass
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Sarcopenia is the process of loss of body mass, specifically the musculoskeletal tissue, with age, which ultimately leads to a syndrome of clinical entity poorly defined as frailty. It is probably as old as humanity itself. Functionally, frailty is described as a syndrome characterized by a progressive decrease in the body's reserve and declining resistance to stressors, possibly because of declining capacity of multiple physiologic systems resulting in higher vulnerability morbidity and mortality. Ayurveda also mentions morbidity occurring with advancing age and various options for its management. Elixirs are recommended in Ayurveda, popularly called 'rasayana', for recovery from the symptoms of frailty. Worldwide, because of the wide demographic profile, the process of ageing exerts its effects on geriatric populations at different ages. Europeans were the first to paraphrase the word frailty for the ageing process. With better medical care and nutrition, a substantial subset of populations survives longer than 60 years or longer worldwide. The most relevant aspect of the recognition of syndrome of frailty is that the process is, to some extent, reversible, provided that adequate attention is paid and a is the primary cause of age-associated reduced basal metabolic rate and decreased energy needs [2] .
Definition
Th e Greek term 'sarcopenia' (meaning 'sarx' for fl esh and 'penia' for loss) describes the loss of muscle mass among older individuals [3] . By the 80th year of age, an average man will lose about 7 kg of muscle mass, whereas an average woman will lose 3.8 kg. Th is is associated with a reduction in the lower extremity strength of up to 50% by this age. Sarcopenia is thus an age-related loss of skeletal muscle mass quality and function and as described in the previous paragraph, physiological dysfunction is noticeable.
Th e European Working Group on Sarcopenia in Older People ( EWGSOP) defi nes it as a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes. Th us, it has been defi ned as a relative appendicular skeletal muscle mass [muscle mass of arms and legs (kg) divided by height 2 (m 2 )] less than two standard deviations below the mean of a same-sex young healthy reference [1] .
However, the latest proposal by Cruz-Jentoft and colleagues is to consider sarcopenia as a 'geriatric syndrome'. Geriatric syndromes manifest by phenotypic characteristics at the physical, morphologic and biochemical levels of an individual as determined by the genotype and the environment. Moreover, the term 'geriatric syndrome' is now used for conditions that are common in old age, which do not fi t in traditional 'disease categories' but result from the accumulated eff ects of multiple predisposing factors that may be precipitated from an acute insult, often associated with multiple comorbidities and poor outcomes such as increased disabilities and decreased quality of life. Th ey are usually the presenting manifestations of multiple underlying diseases and are treatable using a multidisciplinary approach.
Typical 'geriatric syndromes' are delirium, dementia, depression, dizziness, failure to thrive, malnutrition, falls, functional dependence and gait disorders.
Aetiopathogenesis
Various risk factors have been identifi ed. Constitutional factors such as advanced age, low birth weight, several genetic aspects, subclinical infl ammation, hormonal dysregulation involving the growth hormone (GH), testosterone, insulin-like growth factor 1 (IGF-1) and certain habits such as decreased food intake (specifi cally protein intake), minimal physical exercise in one's daily life, use of addictives such as alcohol and tobacco, prolonged bed rest, immobility and chronic debilitating health conditions, poor nutrition, poor social life, lack of family support and care can all lead to the development of sarcopenia ( Fig. 1 ).
Anabolic hormones
Testosterone exerts important anabolic eff ects on muscle. Circulating androgen concentrations decrease in men with increasing age and there is increasing evidence that this may contribute towards the development of sarcopenia and decrease in functional status that may occur with ageing. Serum testosterone level is also related to the appendicular skeletal muscle mass in older women.
Physical activity
Muscle disuse, especially in elderly individuals, causes a major decrease in muscle size and strength, even with adequate protein and energy intake. Prevalence is also sex dependent and increases with age, from less than 5% between 50 and 65 years of age up to 50% in men older than 80 years of age and 30% in women.
Nutrition
Impaired nutritional intake may also lead to the development of sarcopenia. Helms et al. [4] have shown that eating half the recommended dietary allowance of protein 1.0 g/kg/day causes a signifi cant decrease in the strength and body cell mass in postmenopausal women.
Cytokines
Cytokines may also be important in the development of sarcopenia. Older women with higher interleukin-6 levels were recently shown to be at an increased risk of developing mobility disability, impairment in activities of daily living and steeper decrease in walking ability than those with lower interleukin-6 levels, and this may be partially explained by a parallel decline in muscle strength.
Pathological changes in muscle
Qualitative and quantitative changes in muscle are considered to be central to the development of sarcopenia. A decrease in muscle mass, muscle strength and muscle effi ciency (i.e. muscle strength per unit of muscle mass) may be observed with increasing age; disproportionate atrophy of type IIa (fast-twitch) muscle fi bres, decrease in total muscle fi tness, decrease in muscle protein synthesis, unclear separation between slow and fast fi bres, decreased functional units, increased irregularity of muscle unit fi ring and loss of α-motor neuron input to muscle may also occur [2] .
Several mechanisms potentially link obesity and sarcopenia. Obese individuals tend to be less physically active and have lower levels of anabolic hormones such as testosterone, GH and IGF-1. Th ey also have higher levels of proinfl ammatory cytokines and adipokines (leptin, adiponectin and resistin) that induce chronic infl ammation, which may trigger insulin resistance. All these conditions may lead to 'sarcopenic obesity'.
Consequences
As proposed by Fried et al., sarcopenia plays a crucial aetiological role in the frailty process itself, also being a key player in its latent phase and explaining many aspects of the frailty status. Sarcopenia leads, through frailty, to severe eff ects such as repeated falls, multiple and various trauma, functional decline, disability, multiple emergency room visits and hospital admissions, cross-infections, loss of independence, nursing home admission, poor quality of life and ultimately a painful death.
An approach to the diagnosis of sarcopenia
Th e clinical suspicion of sarcopenia on the basis of assessment of multiple risk factors is corroborated by muscle weakness, early fatigue and poor endurance, associated with reduced walking speed, impaired mobility, inabilities in activities of daily activities. Sarcopenia may be evaluated using the three measures defi ned by EWGSOP: loss of muscle mass, with decreased strength and/or physical performance. Strength can be measured using hand-grip strength. Physical performance can be measured using a variety of tests: gait speed, the long corridor walk test, the 6-minute walking test, the timed get-up-and-go test and the stair-climb test. Mortality is strongly associated with habitual gait speed.
Pahor et al. suggest assessing muscle quality using a combined measure of dual-energy X-ray absorptiometry ( DEXA) muscle mass and grip strength as these methods are valid, reliable and specifi c to skeletal muscle, predictive of future health events, noninvasive, practical, low cost and widely accessible. Maden-Wilkinson et al. have used computing imaging softwares for the quadriceps group and other thigh muscles (adductors, hamstrings and abductors) to determine the cross-sectional area of each of the four muscles in each slice (Fig. 2(a) ) Total thigh volume was further estimated by summation of the cross-sectional area of each head of the individual quadriceps muscles across the fi xed length on the femur and further converted into absolute mass by multiplying by 1.04 g/cm 3 (the density of muscle tissue). DEXA was also used to provide estimations of dominant leg lean mass, fat mass and bone mineral content total body using computer software (Fig. 2(b) ).
Prado et al. suggested the use of MRI, which relies on nonionizing radiation for the safety of the patient. Th e MRI technique has been used widely to evaluate Adapted from Sarcopenia as a geriatric syndrome [5] . Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
Figure 1
the quantity and distribution of adipose tissue as well as skeletal muscle mass. Ideally, whole-body imaging provides absolute information; most studies suggest a single MRI technique protocol, especially at the mid-thigh level (Fig. 3) .
A simple way to start the investigation of suspected sarcopenia may be measurement of walking (gait) speed or fi nding out if an individual can sit and stand up from chair fi ve times at the point of initial assessment. If any of these tests is positive (walking speed <0.8 m/s, inability to stand up from a chair), assessment of grip strength and a bioelectrical impedance analysis may easily available methods to evaluate the probability of sarcopenia by measuring the ratio between lean body and fat body ( Figs. 4 and 5 ). Further investigations such as DEXA may be needed considering that the gold-standard measure of the ratio of lean/fat body mass is computed tomography/MRI.
The syndrome of frailty
Normal ageing is accompanied by a number of physiologic changes. When this decline in physiologic reserves reaches across multiple organ systems, a certain threshold is arrived at when any stressor can lead to a sudden decline in functional status and comorbid features. Fried et al. proposed a phenotypic defi nition of frailty that consists of fi ve components: unintentional weight loss, weakness, slowness, self-reported exhaustion (poor endurance) and low physical activity. An individual is classifi ed as frail if at least three of these criteria are fulfi lled. Th ose fulfi lling one or two criteria are classifi ed as prefrail and those fulfi lling no criteria are classifi ed as robust [1] .
Muscle strength was assessed as maximal grip strength (in kilograms) in the dominant hand (average of three measures) using a hand-held dynamometer. Individuals had muscle weakness if their maximal grip strength was in the lowest quintile of the study population (adjusted for sex and BMI). Walking speed was specifi ed as the time needed to walk 15 feet at a normal pace; slowness was defi ned as a value in the lowest quintile (adjusted for sex and standing height). Individuals had poor endurance (exhaustion) if they felt that everything they did was an eff ort.
An affi rmative answer was indicative of decreased maximal oxygen consumption (VO 2 max). Physical activity was estimated by questioning about 18 leisure activities during the last week. A weighted score of kilocalories expended per week was calculated on the basis of these questions. Th e lowest quintile of physical activity was identifi ed for each sex and defi ned as low physical activity.
Recently, the International Academy of Nutrition, Health, and Aging ( IANA) proposed the FRAIL scale [6] , which combines elements of the frailty phenotype with the presence of comorbid diseases. It comprises fi ve domains: fatigue (defi ned as having less energy than in the past), resistance (defi ned as the inability to climb stairs), ambulation (defi ned as the inability to walk one block), number of illnesses Selected body composition components measured by dual-energy X-ray absorptiometry (DEXA; left) and MRI (right). Body mass (M) and volume (V) represent the sum of these components for DEXA and MRI, respectively. BMC, bone mineral content; IMAT, intermuscular adipose tissue; LST, lean soft tissue; Res, residual mass (organs and tissues remaining after subtracting skeletal muscle, bone, and adipose tissue volumes); SAT, subcutaneous adipose tissue; SM, skeletal muscle; VAT, visceral adipose tissue. (defi ned as more than fi ve concurrent illnesses) and loss of weight (more than 5% in 1 year) [1] .
Aetiopathogenesis
Potential determinants of the frailty syndrome induce a catabolic cascade that also aff ects other tissues and organs (e.g. skin atrophy, heart failure), in addition to weakened bones and reduced muscle strength.
(1) Higher levels of white blood cells, proinfl ammatory cytokines and C-reactive protein support a chronic low-grade infl ammatory role in the development of sarcopenia as well as frailty. Infl ammation may be the result of oxidative stress. (2) Certain lifestyle and environmental factors increase the production of reactive oxygen species, which induces changes in gene expression and damage of DNA, proteins and lipids. Th is not only gives rise to more reactive oxygen species but also to infl ammation and proliferation, necrosis and apoptosis at the cellular level, ultimately leading to frailty. In a recent study, cellular senescence and apoptosis were found to play a role in the development of frailty. (3) Increased levels of biomarkers of coagulation and fi brinolysis have also been considered in the pathophysiology of frailty. Indeed, signifi cantly higher levels of d-dimer and factor VIII have been observed in frail elderly individuals and higher levels of d-dimer and tissue plasminogen activator increased the risk of incident frailty. (4) Hormonal changes associated with sarcopenia may also play a role in the development of frailty. (5) Frailty has also been linked to vitamin D defi ciency. Low levels of vitamin D (20 ng/ml) are associated with higher odds of prevalent frailty and an increased risk of incident frailty. Low 25-OH-D may be associated with frailty through several biological pathways, including an eff ect on bone, muscle and the immune system. Besides its well-documented role in osteoporosis and fracture risk, vitamin D defi ciency has been associated with low muscle mass and strength and an increased level of proinfl ammatory cytokines. (6) Also, IGF-1 and insulin resistance may contribute towards frailty as frail elderly individuals have lower IGF-1 levels than nonfrail age-matched individuals.
Screening process of sarcopenia.
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Figure 4
Therapeutic approaches to musculoskeletal frailty [1, 7, 8] Exercise therapy in frail elderly individuals had a positive impact on physical determinants (such as body composition and muscle function) and on functional ability (such as mobility and balance).
A combined exercise programme of long duration (5 months) performed three times a week for 30-45 min led to superior outcomes [7] . Numerous studies have indeed shown that, even in the elderly, progressive resistance training is an eff ective intervention for sarcopenia, signifi cantly improving muscle strength, walking speed and physical activity. To improve muscle power, high-velocity progressive resistance training may be better than the traditional (low velocity) progressive resistance training.
An alternative to resistance training is whole-body vibration training, during which the patient stands on a platform that generates vertical sinusoidal vibrations. Th ese mechanical stimuli activate the muscle spindles, which activates the alpha motor neurons and initiates muscle contraction. Similar to resistance training, vibration training increases both muscle strength and muscle mass. In addition, physical exercise training may also have an eff ect on bone, even in the elderly [9] .
Androgen therapy (testosterone replacement) may also have a benefi cial eff ect in frail elderly individuals by improving muscle mass and strength and BMD. In a meta-analysis of the adverse eff ects of testosterone therapy in adult men, there was no signifi cant eff ect on prostate and cardiovascular outcomes, although further studies are required.
Although the association between vitamin D supplementation and an improvement in physical performance remains controversial, there is increasing evidence that a daily dose of 700-1000 IU vitamin D signifi cantly increases muscle strength in elderly individuals with vitamin D defi ciency, with a reduced risk of falls. In combination with a daily dose of 1000-1200 mg of elementary calcium, vitamin D also reverses age-associated secondary hyperparathyroidism. Th is not only counteracts the negative eff ect of parathormone on muscle but also that on bone, with a resultant benefi cial eff ect on BMD [10, 11] .
Th e use of GH is not recommended in this population because of the adverse eff ects. An alternative therapy may be treatment with growth hormone secretagogues, which regulate the secretion of GH and usually result in fewer adverse eff ects. Oral growth hormone secretagogues have been developed that signifi cantly increased muscle mass and in one trial, physical performance also improved.
Frail elderly individuals benefi t most from osteoporosis treatment. Antiresorptive or anabolic therapy, independent of age, protects against fractures and this protection increases with age. Th us, for every avoided fracture, elderly individuals have greater quality of life [12] .
SARMS (nonsteroidal selective androgen receptor modulators, inhibitors of myostatin, ACE inhibiters, eicosapentaenoic acid and IGF-1) are potentially useful for the frail population, but further trials are ongoing to confi rm their benefi cial eff ects [13, 14] .
Conclusion
Th e frailty syndrome requires a more holistic approach of early detection and management. In our ageing population, it will be a major challenge to off er comprehensive tailor-made care to frail elderly individuals to protect their dignity, quality of life and self-esteem, and to prevent disease complications at an advanced age. Th is will only be possible if we identify frail elderly individuals by focusing on functional defi cits and comorbidity. A comprehensive geriatric assessment enables such a systematic screening for frail elderly individuals in our day-to-day general medical practice.
Summary
Defi ning sarcopenia as a geriatric syndrome can help us to understand its complex pathophysiology and consequences. Early recognition of the fi ve components of frailty is pertinent and includes unintentional weight loss, weakness, slowness, selfreported exhaustion (poor endurance) and low physical activity. Management tools for the frailty syndrome and sarcopenia include assessment of muscle strength, muscle mass and physical performance (gait speed, fi ve time stands from a chair and grip strength). Th e ultimate goal of management is to identify lifestyle and treatment strategies that can prevent or delay the onset of the frailty syndrome [15, 16] .
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